Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Methodological standard · §5

CEI-MS-02 — system suitability and acceptance criteria

The performance the system must demonstrate, and the criteria a result must meet to be reportable.

Document identifier
CEI-MS-02/5
Series
Methodological standard
Version
1.4
Published
02 Feb 2023
Last reviewed
02 Jun 2023
Next review
02 Jun 2026
Identifier
10.71829/cei.meth.2
Certainty
High
Cycle
2023 Q1
Category
Identity

§5System suitability and acceptance criteria

§5.1System suitability

Table 1. System suitability criteria. A determination is reportable only where every criterion is met at the time of analysis.

ParameterCriterionWhat it establishes
Calibration residual across the acquisition range≤ 5 ppmMass accuracy
Resolving power at m/z 1000≥ 5 000; ≥ 30 000 for near-isobaric pairsDiscrimination capability
Charge states observed≥ 2Deconvolution reliability
Sequence coverage, peptides ≤ 20 residues≥ 80 % of interresidue bondsSequence confirmation
Sequence coverage, peptides > 20 residues≥ 60 % of interresidue bondsSequence confirmation

§5.2Acceptance criteria

  • Identity is confirmed where the deconvoluted average mass agrees with the expected value within 2 Da for peptides below 3 kDa and within 3 Da above 3 kDa, and sequence coverage meets the stated threshold.
  • Mass agreement alone, without sequence coverage, is recorded as "composition consistent" and not as "identity confirmed".
  • Where the expected mass is not public, identity cannot be confirmed under this standard and the Institute records the compound as identity-unconfirmable rather than as failing.
  • For the bremelanotide/melanotan-II pair, resolution below 5 000 at m/z 1025 does not distinguish the two compounds and any identity claim so obtained is recorded as not conformant.

§5.3Limitations

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.